Toward a revision of criteria for the dementias

Kenneth Rockwood, Rémi W. Bouchard, Richard Camicioli, Gabriel Léger

Producción científica: Contribución a una revistaArtículo de revisiónrevisión exhaustiva

11 Citas (Scopus)

Resumen

This article critically considers current diagnostic criteria for dementia and reports recommendations approved by at least 80% of experts attending the Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD3). There was consensus that many of the features proposed as essential to a diagnosis of dementia in the 1980s no longer are relevant (for example, the requirements for memory impairment, electroencephalogram and cerebrospinal fluid studies, age-specific exclusions). In addition, other syndromes such as frontotemporal dementia have been recognized and need to inform new dementia criteria. It is also recognized that a diagnosis of depression need not exclude a dementia diagnosis. Other proposals, such as neuropathology should be considered as additional evidence and not as a gold standard or that some people with dementia have prolonged plateaus so that progressive decline need not be a criterion for Alzheimer's disease (AD), were more controversial and did not receive similar support. Given the evidence of the last three decades, there is merit in reconsidering the criteria by which dementia and AD are diagnosed.

Idioma originalEnglish
Páginas (desde-hasta)428-440
Número de páginas13
PublicaciónAlzheimer's and Dementia
Volumen3
N.º4
DOI
EstadoPublished - oct. 2007

Nota bibliográfica

Funding Information:
Rémi W. Bouchard has received support from Pfizer Canada (Consultant, Advisory Board Member, Speaker, Lecturer, Clinical Trials), Novartis (Consultant, Advisory Board Member, Speaker, Lecturer, Clinical Trials), Janssen Ortho Inc. (Consultant, Advisory Board Member, Speaker, Lecturer, Clinical Trials), and Lundbeck Canada (Consultant, Advisory Board Member, Speaker, Lecturer, Clinical Trials).

Funding Information:
Richard Camicioli has received support from Novartis (Grant, Speaker), Pfizer (Grant, Medical Advisory Board Member, Speaker), Janssen-Ortho (Medical Advisory Board Member, Speaker), and GlaxoSmithKline (Medical Advisory Board Member).

Funding Information:
Kenneth Rockwood has received support from Pfizer Canada (Consultant, Medical Advisory Board Member, Speaker), Janssen Ortho Inc. (Consultant, Medical Advisory Board Member, Research Grant Holder), Novartis (Speaker, Consultant), Lundbeck Canada (Advisory Board Member), Merck Frosst (Speaker), CIHR (Research and Career Award Holder), Alzheimer Society of Canada (Research Grant Holder), Dalhousie Medical Research Foundation (Career Award Holder), and the Nova Scotia Department of Health (Consultant).

Funding Information:
Kenneth Rockwood is supported by an Investigator Award from the Canadian Institutes of Health Research (CIHR) and the Dalhousie Medical Research Foundation as the Kathryn Allen Weldon Professor of Alzheimer’s Research. He receives research support from the CIHR and from the Alzheimer Society of Canada.

ASJC Scopus Subject Areas

  • Epidemiology
  • Health Policy
  • Developmental Neuroscience
  • Clinical Neurology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience

PubMed: MeSH publication types

  • Journal Article

Huella

Profundice en los temas de investigación de 'Toward a revision of criteria for the dementias'. En conjunto forman una huella única.

Citar esto